ClinicalTrials.gg
CompletedNCT01584830CONCURUpdated Feb 8, 2016

Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

A Phase 3 interventional study of Regorafenib (BAY73-4506) and Placebo in Colorectal Neoplasms, sponsored by Bayer. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-08.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Enrollment
9th of 58
204 · median 55
Started
2012
the only one that year
Phase 3
7 of 59
1 open now
Registered
6th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 9th largest by enrollment of the 58 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 3, and was the 6th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess if Regorafenib in combination with best supportive care will slow down tumor progression and result in increased survival in patients with metastatic colorectal cancer.

03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • Regorafenib
  • Colorectal
  • Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
  • Subjects with colorectal cancer(CRC) (Stage IV).
  • Subjects must have failed at least two .
  • Progression during or within 3 months following the last administration of approved standard therapies which must include a fluoropyrimidine, oxaliplatin and irinotecan.

    • Subjects treated with oxaliplatin in an setting should have progressed during or within 6 months of completion of adjuvant therapy.
    • Subjects who progress more than 6 months after completion of oxaliplatin containing adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible.
    • Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study.
    • Subjects may have received prior treatment with Avastin (bevacizumab) and/or Erbitux (cetuximab)/Vectibix (panitumumab) (if KRAS WT)
  • Metastatic CRC subjects must have measurable or non according to (RECIST) criteria, version 1.1.
  • (ECOG) Performance Status of 1.
  • of at least 3 months.
  • Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with Regorafenib.
  • Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
  • Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization.
  • Cardiological disease including Congestive heart failure, Unstable angina, Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy.
  • Uncontrolled hypertension. (Systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg despite optimal medical management).
  • Subjects with phaeochromocytoma.
  • Pleural effusion or ascites that causes respiratory compromise.
  • Arterial or venous thrombotic or embolic events.
  • Any history of or currently known .
  • Interstitial lung disease with ongoing signs and symptoms at the time of .
  • Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 week.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Regorafenib (BAY73-4506)

  • Placebo comparator
    Arm 2

    Drug: Placebo

Interventions

  • Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)

  • DrugPlacebo

    Placebo will be given 3 weeks on/1 week off (160 mg od po.)

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.

    Time frame: From randomization of the first subject untill 154 death events observed, up to 2 years

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from date of randomization to disease progression radiological/clinical or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.

    Time frame: From randomization of the first subject untill 154 death events observed, up to 2 years

  2. The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR).

    Time frame: From randomization of the first subject untill 154 death events observed, up to 2 years

  3. Disease Control Rate (DCR)

    DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating)

    Time frame: From randomization of the first subject untill 154 death events observed, up to 2 years

  4. Safety variables will be summarized using descriptive statistics based on adverse events collection

    Time frame: From randomization of the first subject untill 154 death events observed, up to 2 years

07

Study locations

25 sites
  • Guangzhou, Guangdong 510060, China
  • Guangzhou, Guangdong 510080, China
  • Harbin, Heilongjiang 150056, China
  • Nanjing, Jiangsu 210002, China
  • Xi'an, Shaanxi 710032, China
  • Qingdao, Shandong 266003, China
  • Chengdu, Sichuan 610041, China
  • Hangzhou, Zhejiang 310016, China
  • Beijing, 100021, China
  • Beijing, 100071, China
  • Beijing, 100142, China
  • Changchun, 130021, China
  • Shanghai, 200030, China
  • Shanghai, 200032, China
  • Shanghai, 200080, China
  • Tianjin, 300060, China
  • Shatin, New Territories, Hong Kong
  • Hong Kong, Hong Kong
  • Seoul, Korea 138-736, Korea, Republic of
  • Taipei, 10016, Taiwan
  • Taipei, 11217, Taiwan
  • Taoyuan, 333, Taiwan
  • Hanoi, Vietnam
  • Hcmc, Vietnam
  • Ho Chi Minh City, 84, Vietnam
08

References and documents

Publications

  • Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW; CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13. PubMed 25981818 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Nov 2013 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2012
First posted
Apr 25, 2012
Start
Apr 2012
Primary completionActual
Nov 2013
CompletionActual
Jan 2016
Last update
Feb 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01584830
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 25, 2012
Start date
Apr 2012
Primary completion
Nov 2013
Completion
Jan 2016
Last update
Feb 8, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion